Cannabinoid-1 Receptor Blockade in Cardiometabolic Risk Reduction: Safety, Tolerability, and Therapeutic Potential

American Journal of Cardiology

Volumn 100, Issue 12 SUPPL. 1, 2007, Pages

  Steinberg, Benjamin A ^a   Cannon, Christopher P ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR ANTAGONIST; PHENTERMINE; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABNORMAL DREAMING; AGGRESSION; AGITATION; AMNESIA; ANXIETY; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HEADACHE; HEART MUSCLE METABOLISM; HUMAN; HYPESTHESIA; INSOMNIA; ISCHIALGIA; LIBIDO; LIPID BLOOD LEVEL; MAJOR DEPRESSION; MEMORY DISORDER; MIGRAINE; MOOD DISORDER; NAUSEA; NERVOUSNESS; NIGHTMARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANIC; PARESTHESIA; PERIPHERAL NEUROPATHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION; SIDE EFFECT; SLEEP DISORDER; STRESS; TREMOR; WAIST CIRCUMFERENCE;

CARDIOVASCULAR DISEASES; DRUG TOLERANCE; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RISK FACTORS; TREATMENT OUTCOME;

EID: 37249084626     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.10.011     Document Type: Article

References (27)

1. Eriksson K.F., and Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Mälmo Preventive Trial with diet and exercise. Diabetologia 41 (1998) 1010-1016
2. Wadden T.A., Anderson D.A., and Foster G.D. Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions. Obes Res 7 (1999) 170-178
3. Aronne L.J., and Isoldi K.K. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. Am J Cardiol 100 Suppl 12A (2007) 18P-26P
4. Flum D.R., Salem L., Elrod J.A., Dellinger E.P., Cheadle A., and Chan L. Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. JAMA 294 (2005) 1903-1908
5. Buchwald H., Avidor Y., Braunwald E., Jensen M.D., Pories W., Fahrbach K., and Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
6. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
7. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
8. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87 (1990) 1932-1936
9. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
10. 1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 41 (2003) 657-664
11. Liu J., Gao B., Mirshahi F., Sanyal A.J., Khanolkar A.D., Makriyannis A., and Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346 (2000) 835-840
12. 1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118 (1996) 2023-2028
13. Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
14. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
15. Van Gaal L.F. 2-Year data from the RIO-Europe study: metabolic effects of rimonabant in overweight/obese patients. Presented at the American College of Cardiology 2005 Annual Scientific Sessions; March 6-9 (2005) Orlando, Florida
16. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
17. Scheen A.J., Finer N., Hollander P., Jensen M.D., and Van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
18. US Food and Drug Administration Briefing Document, NDA 21-888 (2007). www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4306b1-fda-backgrounder.pdf Zimulti (rimonabant) tablets, 20 mg; sanofi-aventis, Advisory Committee; June 13, Accessed
19. Zigmond A.S., and Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67 (1983) 361-370
20. Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Ultrasound Study (STRADIVARIUS). http://www.clinicaltrials.gov/ct/show/NCT00124332 Accessed November 15, 2007
21. Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes (CRESCENDO). http://www.clinicaltrials.gov/ct/show/NCT00263042 Accessed November 15, 2007
22. Fattore L., Spano M.S., Deiana S., Melis V., Cossu G., Fadda P., and Fratta W. An endocannabinoid mechanism in replapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res Rev 53 (2007) 1-16 Epub 2006 July 12
23. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmactherapy. Pharmacol Rev 58 (2006) 389-462
24. 1 cannabinoid receptors in haemorrhagic shock. Nature 390 (1997) 518-521
25. Varga K., Wagner J.A., Bridgen D.T., and Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12 (1998) 1035-1044
26. Wagner J.A., Hu K., Bauersachs J., Karcher J., Wiesler M., Goparaju S.K., Kunos G., and Ertl G. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 38 (2001) 2048-2054
27. 1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7 (2001) 827-832